BioPorto advances US regulatory pathway for adult AKI test following FDA feedback
The company has expanded its US clinical validation study to support a future FDA submission for its adult NGAL kidney injury test while continuing to grow adoption of the biomarker in clinical practice.
BioPorto has announced progress in its US regulatory strategy for its ProNephro AKI® (NGAL) test by expanding its adult clinical validation study following FDA pre-submission feedback, alongside reporting continued underlying growth in its NGAL business.
The development is significant for healthcare providers and diagnostics developers because it represents another step towards potential FDA clearance of an adult acute kidney injury biomarker test, although regulatory approval remains several years away.
Field | Content |
Alert Type | Industry Update |
Topic | Acute kidney injury diagnostics; regulatory development |
Organisation(s) | BioPorto A/S; US Food and Drug Administration (FDA) |
Affected Stakeholders | Hospital laboratories, nephrologists, critical care clinicians, diagnostics companies and healthcare providers using acute kidney injury biomarkers |
Therapy Area(s) | Nephrology; In Vitro Diagnostics |
Geography | United States |
What Happened | On 20 August 2026, BioPorto announced that, following FDA pre-submission feedback, it is expanding its ProNephro AKI® U.S. Adult Urine NGAL Validation Study from approximately 500 to around 900 patients to strengthen a planned 510(k) submission. The company activated its first US clinical study site earlier in the week and now expects potential FDA clearance for the adult indication in mid-2028. This is a regulatory development rather than an approval or change in clinical practice. (Via Ritzau) |
Why It Matters | Adult acute kidney injury remains an area of significant unmet diagnostic need, and FDA clearance would expand the use of BioPorto's NGAL biomarker beyond its existing paediatric indication in the US. The expanded study reflects FDA feedback intended to strengthen the clinical evidence supporting any future regulatory submission. (attachment.news.eu.nasdaq.com) |
Supporting Context | BioPorto already markets NGAL tests in multiple countries and holds FDA clearance for paediatric use in the United States. The company also reported underlying NGAL revenue growth after adjusting for the impact of a voluntary product recall announced earlier in 2026. (Via Ritzau) |
Who Is Most Affected | Hospital laboratories and clinicians managing patients at risk of acute kidney injury are most directly affected, as future FDA clearance could expand access to NGAL-based testing in adult patients. Diagnostics developers monitoring the AKI biomarker market may also be affected by the evolving regulatory pathway. (Via Ritzau) |
Industry Impact | The expanded validation study could strengthen the evidence base for NGAL testing in adults and may influence competition within the acute kidney injury diagnostics market if FDA clearance is ultimately obtained. However, any commercial or clinical impact depends on successful completion of the study and future regulatory review. (attachment.news.eu.nasdaq.com) |
Key Takeaway | BioPorto has advanced its FDA strategy for adult NGAL testing by expanding its US validation study, but regulatory clearance remains dependent on completion of the enlarged clinical programme and a successful 510(k) review. (Via Ritzau) |
What to Watch | Completion of patient enrolment in the expanded validation study, submission of the planned 510(k) application and the FDA's review of the adult indication, which BioPorto currently expects could conclude in mid-2028. (attachment.news.eu.nasdaq.com) |
Primary Source | |
Relevant Date | 20 August 2026 |
Comentarios